发布求助
文献互助 智能选刊 最新文献

Drugs of The Future最新文献

筛选
英文 中文
NME Digest - April 2022 NME文摘- 2022年4月
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.4.3425322
X. Bofill, P. Cole, D. Fernández-Forner
{"title":"NME Digest - April 2022","authors":"X. Bofill, P. Cole, D. Fernández-Forner","doi":"10.1358/dof.2022.47.4.3425322","DOIUrl":"https://doi.org/10.1358/dof.2022.47.4.3425322","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66443668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cefepime/enmetazobactam. Beta-Lactam/beta-lactamase inhibitor, Treatment of complicated urinary tract infection 头孢吡肟/ enmetazobactam。β -内酰胺/ β -内酰胺酶抑制剂，治疗复杂性尿路感染
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.7.3408811
A. Akhir, A. Dasgupta, S. Chopra
{"title":"Cefepime/enmetazobactam. Beta-Lactam/beta-lactamase inhibitor, Treatment of complicated urinary tract infection","authors":"A. Akhir, A. Dasgupta, S. Chopra","doi":"10.1358/dof.2022.47.7.3408811","DOIUrl":"https://doi.org/10.1358/dof.2022.47.7.3408811","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66444759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Clinical Disclosures and SMR Award. Highlights from the Society for Medicines Research Conference. Virtual - December 2, 2021 最近的临床披露和SMR奖。来自医学研究学会会议的亮点。虚拟- 2021年12月2日
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.8.3447439
M. Swarbrick, M. Hann, D.H. O'Donovan, M. Alavijeh, P. Jeffrey, K. Brown
{"title":"Recent Clinical Disclosures and SMR Award. Highlights from the Society for Medicines Research Conference. Virtual - December 2, 2021","authors":"M. Swarbrick, M. Hann, D.H. O'Donovan, M. Alavijeh, P. Jeffrey, K. Brown","doi":"10.1358/dof.2022.47.8.3447439","DOIUrl":"https://doi.org/10.1358/dof.2022.47.8.3447439","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66445740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic targets for dermatomyositis 皮肌炎的治疗靶点
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.9.3461263
L. Sorbera, C. Dulsat, A. Graul
{"title":"Therapeutic targets for dermatomyositis","authors":"L. Sorbera, C. Dulsat, A. Graul","doi":"10.1358/dof.2022.47.9.3461263","DOIUrl":"https://doi.org/10.1358/dof.2022.47.9.3461263","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66446083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Taletrectinib adipate. Dual ROS1 and NTRK inhibitor, Treatment of non-small cell lung cancer, Treatment of solid tumors Taletrectinib己二酸。ROS1和NTRK双重抑制剂，治疗非小细胞肺癌，治疗实体瘤
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.7.3413462
Z. Zhang, C. Gao, X. Ma, Z. Li, C. Ashby, L. Wei, Z. Chen
{"title":"Taletrectinib adipate. Dual ROS1 and NTRK inhibitor, Treatment of non-small cell lung cancer, Treatment of solid tumors","authors":"Z. Zhang, C. Gao, X. Ma, Z. Li, C. Ashby, L. Wei, Z. Chen","doi":"10.1358/dof.2022.47.7.3413462","DOIUrl":"https://doi.org/10.1358/dof.2022.47.7.3413462","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66444411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Furaprevir. HCV NS3/4A protease inhibitor, Treatment of chronic hepatitis C virus infection tract infection Furaprevir。HCV NS3/4A蛋白酶抑制剂治疗慢性丙型肝炎病毒感染道感染
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.8.3440035
P. Ghosh, V. Nehra, Z. Temesgen
{"title":"Furaprevir. HCV NS3/4A protease inhibitor, Treatment of chronic hepatitis C virus infection tract infection","authors":"P. Ghosh, V. Nehra, Z. Temesgen","doi":"10.1358/dof.2022.47.8.3440035","DOIUrl":"https://doi.org/10.1358/dof.2022.47.8.3440035","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66445698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Danuglipron. Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity Danuglipron。胰高血糖素样肽1受体激动剂，治疗2型糖尿病，治疗肥胖
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.6.3373535
A. Sperry, J. Hardy, R. Goldfaden, A. Hurst, A. Ashchi, D. Sutton, M. Sheikh-Ali, J. Huston, R. Choksi
{"title":"Danuglipron. Glucagon-like peptide 1 receptor agonist, Treatment of type 2 diabetes, Treatment of obesity","authors":"A. Sperry, J. Hardy, R. Goldfaden, A. Hurst, A. Ashchi, D. Sutton, M. Sheikh-Ali, J. Huston, R. Choksi","doi":"10.1358/dof.2022.47.6.3373535","DOIUrl":"https://doi.org/10.1358/dof.2022.47.6.3373535","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66444663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
European Federation of Medicinal Chemistry - XXVII International Symposium on Medicinal Chemistry (EFMC-ISMC 2022). Nice - September 4-8, 2022 欧洲药物化学联合会-第二十七届国际药物化学研讨会(EFMC-ISMC 2022)。尼斯——2022年9月4日至8日
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.11.3500032
A. Fernández-Llamazares, P. Cole, X. Bofill
{"title":"European Federation of Medicinal Chemistry - XXVII International Symposium on Medicinal Chemistry (EFMC-ISMC 2022). Nice - September 4-8, 2022","authors":"A. Fernández-Llamazares, P. Cole, X. Bofill","doi":"10.1358/dof.2022.47.11.3500032","DOIUrl":"https://doi.org/10.1358/dof.2022.47.11.3500032","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66441679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Society for Immunotherapy of Cancer (SITC) - 36th Annual Meeting. Virtual - November 10-14, 2021 癌症免疫治疗学会(SITC)第36届年会。虚拟- 2021年11月10日至14日
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.2.3393240
J. Toldrà
{"title":"Society for Immunotherapy of Cancer (SITC) - 36th Annual Meeting. Virtual - November 10-14, 2021","authors":"J. Toldrà","doi":"10.1358/dof.2022.47.2.3393240","DOIUrl":"https://doi.org/10.1358/dof.2022.47.2.3393240","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66442455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Zandelisib. Phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor, Treatment of B-cell lymphomas Zandelisib。磷脂酰肌醇3-激酶δ (PI3Kdelta)抑制剂，治疗b细胞淋巴瘤
IF 0.2 4区 医学
Drugs of The Future Pub Date : 2022-01-01 DOI: 10.1358/dof.2022.47.8.3427161
Q. Lu, Y. Xie, Z. Zhu, G. Huang, C. Ashby, Z. Chen
{"title":"Zandelisib. Phosphatidylinositol 3-kinase delta (PI3Kdelta) inhibitor, Treatment of B-cell lymphomas","authors":"Q. Lu, Y. Xie, Z. Zhu, G. Huang, C. Ashby, Z. Chen","doi":"10.1358/dof.2022.47.8.3427161","DOIUrl":"https://doi.org/10.1358/dof.2022.47.8.3427161","url":null,"abstract":"","PeriodicalId":11366,"journal":{"name":"Drugs of The Future","volume":"1 1","pages":""},"PeriodicalIF":0.2,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66444958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信
小红书